Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.17%358.711.2%$830.53m
AMGNAmgen Inc.
-0.66%190.491.2%$543.11m
CELGCelgene Corporation
-0.28%85.101.2%$507.54m
GILDGilead Sciences, Inc.
0.42%77.370.9%$473.45m
VRTXVertex Pharmaceuticals Incorporated
-1.51%177.401.9%$313.54m
REGNRegeneron Pharmaceuticals, Inc.
-0.17%367.112.6%$276.88m
ILMNIllumina, Inc.
0.66%311.153.5%$269.38m
BLUEBluebird Bio, Inc.
0.78%180.3515.7%$197.52m
SRPTSarepta Therapeutics, Inc.
-1.64%133.3116.6%$196.81m
ALXNAlexion Pharmaceuticals, Inc.
0.05%135.162.0%$178.57m
NKTRNektar Therapeutics
-0.71%48.735.6%$172.03m
EXASExact Sciences Corporation
0.02%67.6225.4%$155.70m
EXELExelixis, Inc.
-0.23%21.296.4%$135.36m
BMRNBioMarin Pharmaceutical Inc.
-0.94%101.904.4%$122.64m
AAgilent Technologies, Inc.
-0.45%63.861.5%$110.57m

Company Profile

Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.